mRx-7: A new weapon for cancer
miReven
miReven is a biopharmaceutical company focused on developing mRx-7 as a new cancer therapy. The world of RNA-based therapeutics is an entirely new clinical treatment.
Our Science
mRx-7 is a synthetic small double stranded RNA (dsRNA) chemically modified mimic of microRNA-7 (miR-7) that we have designed, which is a potent inhibitor of…
Investors
miReven welcomes new partnerships. Please contact us for information about investing in our company.
